Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Michel Afargan"'
Autor:
Mor Oron-Herman, David Kirmayer, Amelie Lupp, Stefan Schulz, Genady Kostenich, Michel Afargan
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract Somatostatin receptors are clinically validated GPCR biomarkers for diagnosis and treatment of various neuroendocrine tumors (NET). Among the five somatostatin receptors, SST2 and SST3 are associated with apoptosis and cell cycle arrest, mak
Externí odkaz:
https://doaj.org/article/c0f0d22b062e45908917da22f1d691b0
Autor:
Ekaterine Goliadze, Lanqi Jia, Eric J. Brown, Michel Afargan, Tina Gill, Ryan L. Ragland, Erin George, Fiona Simpkins, Dansu Li, Oren Gilad, Sahithi Pamarthy, Laura R. Butler
Publikováno v:
Cancer Research. 79:3498-3498
Ataxia Telangiectasia and Rad3-related (ATR) and its downstream effector Checkpoint Kinase 1 (CHK1) are central to the protection of stalled replication forks.Specific targeting of the ATR is synthetically lethal with multiple cancer-associated chang
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1842f4323a2d9eeb3ab3ae2da63f8a4f
https://doi.org/10.1158/1538-7445.am2019-3498
https://doi.org/10.1158/1538-7445.am2019-3498
Autor:
Michael Friedman, David Kirmayer, Yael Mardor, Eytan Moor, Amnon Hoffman, Noa Lapidot, Michel Afargan, Leonid Kagan
Publikováno v:
Journal of Controlled Release. 113:208-215
The purpose of this study was to evaluate the ability of the Accordion Pill (AP), a novel controlled release gastroretentive unfolding dosage form (DF), to increase the bioavailability of riboflavin (RF) in humans. Three formulations containing 75 mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cde3c4b3681b4e1babdf6c388533ddb
https://doi.org/10.1016/j.jconrel.2006.03.022
https://doi.org/10.1016/j.jconrel.2006.03.022
Autor:
Daniel Landau, Andrey Podshyvalov, Yael Segev, Leonid Katchko, Michel Afargan, Aviva Silbergeld, Moshe Phillip
Publikováno v:
Kidney International. 60:505-512
A novel somatostatin analogue prevents early renal complications in the nonobese diabetic mouse . Background PTR-3173 (S) is a novel somatostatin analogue that has been found to exert a prolonged inhibitory action on the growth hormone (GH)-insulin-l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e81de3f04484792829f065666d20635
https://doi.org/10.1046/j.1523-1755.2001.060002505.x
https://doi.org/10.1046/j.1523-1755.2001.060002505.x
Autor:
Thuy-Anh Tran, Michel Afargan, Oved Amitay, John E. Taylor, Ofer Ziv, Daniel Hoyer, Murray Goodman, Ralph-Heiko Mattern, Barry A. Morgan
Publikováno v:
Journal of Medicinal Chemistry. 41:2679-2685
We report the synthesis, bioactivity, and structure-activity relationship studies of compounds related to the Merck cyclic hexapeptide c[Pro6-Phe7-d-Trp8-Lys9-Thr10-Phe11], L-363,301 (the numbering in the sequence refers to the position of the residu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88f18b8b0abd31260dedeebf38fcb637
https://doi.org/10.1021/jm970393l
https://doi.org/10.1021/jm970393l
Autor:
Chaim Gilon, Moshe Bracha, Sharon Gazal, Olga Karpov, Ofer Ziv, Michel Afargan, Garry Gelerman, Pninit Litman
Publikováno v:
Journal of medicinal chemistry. 45(8)
Somatostatin-14 (somatostatin) and its clinically available analogues octreotide, lanreotide, and vapreotide are potent inhibitors of growth hormone, insulin, and glucagon release. Recently, a novel backbone cyclic somatostatin analogue c(GABA-Phe-Tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f6b852fd2a964da6a2ac8b9978bed56
https://pubmed.ncbi.nlm.nih.gov/11931620
https://pubmed.ncbi.nlm.nih.gov/11931620
Autor:
Offer Ziv, Michel Afargan, Rakefet Rosenfeld, David Stephensky, Dvira Shohat, Moshe Bracha, George Liapakis, Amnon Hoffman, Olga Karpov, Garry Gelerman, Amnon Wolf, Eva Tiensuu Janson, Kjell Öberg, Chaim Gilon
Publikováno v:
Endocrinology. 142(1)
Somatostatin, also known as somatotropin release-inhibiting factor (SRIF), is a natural cyclic peptide inhibitor of pituitary, pancreatic, and gastrointestinal secretion. Its long-acting analogs are in clinical use for treatment of various endocrine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8266135168b651446957098155b047c
https://pubmed.ncbi.nlm.nih.gov/11145612
https://pubmed.ncbi.nlm.nih.gov/11145612
Autor:
Sharon Gazal, Gary Gellerman, Ofer Ziv, Olga Karpov, Pninit Litman, Moshe Bracha, Michel Afargan, Chaim Gilon
Publikováno v:
Peptides: The Wave of the Future ISBN: 9789401039055
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85e0e80fd4b9acefa281fb9089ba69f9
https://doi.org/10.1007/978-94-010-0464-0_291
https://doi.org/10.1007/978-94-010-0464-0_291
Autor:
Offer Ziv, Michel Afargan, Rakefet Rosenfeld, Eva Tiensuu Janson, Olga Karpov, Garry Gelerman, Kjell Öberg, Moshe Bracha
Publikováno v:
Regulatory Peptides. 94:74
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cddd168caa00397477194232772d4932
https://doi.org/10.1016/s0167-0115(00)80149-4
https://doi.org/10.1016/s0167-0115(00)80149-4